Hyperion Therapeutics Inc (HPTX) financial statements (2022 and earlier)

Company profile

Business Address 2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments137,283102,27749,853
Cash and cash equivalents102,79674,23249,853
Short-term investments34,48728,045 
Receivables14,8644,419 
Inventory, net of allowances, customer advances and progress billings4,6213,513
Inventory4,6213,513 
Prepaid expense and other current assets1,155
Other undisclosed current assets2,6321,403 
Total current assets:159,400111,61251,008
Noncurrent Assets
Property, plant and equipment1,11693649
Long-term investments and receivables9,22615,780 
Long-term investments9,22615,780 
Intangible assets, net (including goodwill)8,81613,442
Intangible assets, net (excluding goodwill)8,81613,442 
Other noncurrent assets1,858749
Prepaid expense and other noncurrent assets147
Total noncurrent assets:21,01630,907196
TOTAL ASSETS:180,416142,51951,204
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities34,87519,0836,174
Accounts payable4,6692,2922,177
Accrued liabilities25,50912,1872,540
Employee-related liabilities4,1344,2781,457
Taxes payable563326 
Debt 5,6524,348
Deferred revenue and credits224  
Other undisclosed current liabilities(4,697)(4,604)(1,457)
Total current liabilities:30,40220,1319,065
Noncurrent Liabilities
Long-term debt and lease obligation18,1242,6217,750
Long-term debt, excluding current maturities18,1242,6217,750
Liabilities, other than long-term debt33881 
Deferred revenue and credits33881 
Total noncurrent liabilities:18,4622,7027,750
Total liabilities:48,86422,83316,815
Stockholders' equity
Stockholders' equity attributable to parent131,552119,68634,389
Common stock222
Additional paid in capital260,225242,109173,384
Accumulated other comprehensive loss(50)(55) 
Accumulated deficit(128,625)(122,370)(138,997)
Total stockholders' equity:131,552119,68634,389
TOTAL LIABILITIES AND EQUITY:180,416142,51951,204

Income statement (P&L) ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
113,58442,204 
Cost of revenue(13,727)(6,740) 
Gross profit:99,85735,464 
Operating expenses(117,791)(55,621)(28,533)
Other undisclosed operating income13,7276,740 
Operating loss:(4,207)(13,417)(28,533)
Nonoperating income (expense)(151)553(27)
Investment income, nonoperating5552712
Other nonoperating income (expense)(699)526(39)
Interest and debt expense(1,001)(1,539)(3,703)
Loss from continuing operations before equity method investments, income taxes:(5,359)(14,403)(32,263)
Other undisclosed income (loss) from continuing operations before income taxes(593)31,079 
Income (loss) from continuing operations before income taxes:(5,952)16,676(32,263)
Income tax expense(303)(49) 
Net income (loss) available to common stockholders, diluted:(6,255)16,627(32,263)

Comprehensive Income ($ in thousands)

12/31/2014
12/31/2013
12/31/2012
Net income (loss):(6,255)16,627(32,263)
Other comprehensive income (loss)5(55) 
Comprehensive income (loss), net of tax, attributable to parent:(6,250)16,572(32,263)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: